The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Drs Ansell, Armand, and Diefenbach discuss the latest research into the use of checkpoint inhibition in Hodgkin lymphoma.
This activity is intended for hematologists, pathologists, and other healthcare professionals who treat patients with Hodgkin lymphoma.The goal of this activity is to discuss the recent advances in the use of immunotherapy for Hodgkin lymphoma.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 14, 2017 - Nov. 14, 2018
Developed through a partnership between SITC and Medscape.
 |
 |
- Have increased knowledge regarding the role of immune escape in the development of Hodgkin lymphoma (HL)
- Have increased knowledge regarding the clinical data on the efficacy of immunotherapy for the treatment of Hodgkin lymphoma
- Have greater competence related to their ability to manage side effects associated with checkpoint inhibitor therapy
AMA PRA Category 1 Credit(s)™: 0.50
ABIM MOC Part 2 Credits: 0.50
Contact Hour: 0.50